- ICH GCP
- Registre des essais cliniques de l'UE
Derniers essais
EudraCT Number: 2022-003865-39 | Sponsor Protocol Number: WSG-AM12 | Start Date: 2023-05-04 | ||||||||||||||||
Sponsor Name: Westdeutsche Studiengruppe GmbH | ||||||||||||||||||
Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer | ||||||||||||||||||
Medical condition: HER2+ early breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003951-41 | Sponsor Protocol Number: BFS-AS-40184 | Start Date: 2023-05-04 | ||||||
Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||
Full Title: CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus th... | ||||||||
Medical condition: Asthma | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000033-33 | Sponsor Protocol Number: 83631 | Start Date: 2023-05-03 | |||||||||||||||||||||
Sponsor Name: Maastricht University | |||||||||||||||||||||||
Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance. | |||||||||||||||||||||||
Medical condition: Hereditary fructose intolerance | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003056-14 | Sponsor Protocol Number: VTX958-203 | Start Date: 2023-05-03 | |||||||||||
Sponsor Name: Ventyx Biosciences, Inc | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis | |||||||||||||
Medical condition: Active Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004411-11 | Sponsor Protocol Number: NeoTreme | Start Date: 2023-05-03 | |||||||||||
Sponsor Name: University Hospital Schleswig-Holstein, Campus Lübeck | |||||||||||||
Full Title: Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme) | |||||||||||||
Medical condition: Intrahepatic cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003452-14 | Sponsor Protocol Number: SBC007C401 | Start Date: 2023-05-02 | |||||||||||
Sponsor Name: Berlin Cures GmbH | |||||||||||||
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability... | |||||||||||||
Medical condition: long Covid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003532-73 | Sponsor Protocol Number: ADVANCE-AD04-001 | Start Date: 2023-05-02 | ||||||||||||||||
Sponsor Name: ADvantage Therapeutics GmbH | ||||||||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE | ||||||||||||||||||
Medical condition: early Alzheimer’s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Ongoing) BG (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005551-36 | Sponsor Protocol Number: NL79416.018.21 | Start Date: 2023-05-01 | ||||||
Sponsor Name: Amsterdam University Medical Center, AMC | ||||||||
Full Title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized... | ||||||||
Medical condition: Myocardial infarction related cardiogenic shock | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DK (Trial now transitioned) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003866-19 | Sponsor Protocol Number: 83336 | Start Date: 2023-05-01 | ||||||
Sponsor Name: Amsterdam UMC location AMC | ||||||||
Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women | ||||||||
Medical condition: Osteoporosis prevention | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003004-33 | Sponsor Protocol Number: AR-DEX-22-01 | Start Date: 2023-04-26 | |||||||||||
Sponsor Name: Areteia Therapeutics, Inc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe ... | |||||||||||||
Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |